Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P-Glycoprotein Functioning as an Absorption Barrier

Because the significance of P‐glycoprotein in the in‐vivo secretion of β‐blockers in intestinal epithelial cells is unclear, the secretory mechanism for β‐blockers and other drugs has been evaluated. Uptake of the β‐blockers acebutolol, celiprolol, nadolol and timolol, and the antiarrhythmic agent,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy and pharmacology 1996-10, Vol.48 (10), p.1083-1089
Main Authors: Terao, Toshimitsu, Hisanaga, Etsuko, Sai, Yoshimichi, Tamai, Ikumi, Tsuji, Akira
Format: Article
Language:English
Subjects:
Adenosine Triphosphate - analysis
Adrenergic beta-Antagonists - pharmacokinetics
Animals
ATP Binding Cassette Transporter, Subfamily B, Member 1 - physiology
Biological and medical sciences
Caco-2 Cells
Cyclosporine - pharmacology
Drug Resistance
Epithelium - metabolism
General pharmacology
Humans
Intestinal Absorption - drug effects
Intestine, Small - blood supply
Intestine, Small - metabolism
Ischemia - metabolism
Male
Medical sciences
Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions
Pharmacology. Drug treatments
Rats
Rats, Wistar
Vinblastine - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Because the significance of P‐glycoprotein in the in‐vivo secretion of β‐blockers in intestinal epithelial cells is unclear, the secretory mechanism for β‐blockers and other drugs has been evaluated. Uptake of the β‐blockers acebutolol, celiprolol, nadolol and timolol, and the antiarrhythmic agent, quinidine by the multidrug‐resistant leukaemic cell line variant K562/ADM was significantly lower than that by drug‐sensitive K562 cells, suggesting that these β‐blockers are transported by P‐glycoprotein out of cells. The reduced uptake of acebutolol by the drug‐resistant K562/ADM cells was reversed by treating the cells with anti‐P‐glycoprotein monoclonal antibody, MRK16, whereas no such alteration in uptake was observed for drug‐sensitive K562 cells. Acebutolol uptake by K562/ADM cells was, moreover, markedly enhanced, in a concentration‐dependent manner, in the presence of the specific P‐glycoprotein inhibitors, MS‐209 and cyclosporin. Caco‐2 cells were used for evaluation of the role of P‐glycoprotein in intestinal permeability to drugs in‐vitro. Basolateral‐to‐apical transport of acebutolol was twice that in the reverse direction. A similar polarized flux was also observed in the transport of vinblastine, but not in that of acetamide or mannitol. When in‐vivo intestinal absorption was evaluated by the rat jejunal loop method, with simultaneous intravenous administration of a P‐glycoprotein inhibitor, cyclosporin, intestinal absorption of both acebutolol and vinblastine increased 2.6‐ and 2.2‐fold, respectively, but no such enhancement was observed in the absorption of acetamide. The effect of cyclosporin on the intestinal absorption of several drugs was further examined, and the extent of the contribution of P‐glycoprotein as an absorption barrier to those drugs was evaluated. ATP depletion by occlusion of the superior mesenteric artery resulted in a clear increase in epithelial permeability to vinblastine, but not to 3‐O‐methylglucose or acetamide, indicating that vinblastine is secreted by ATP‐dependent P‐glycoprotein into the lumen. These findings demonstrate that P‐glycoprotein plays a role as an absorption barrier by transporting several drugs from intestinal cells into the lumen.
ISSN:0022-3573
2042-7158
DOI:10.1111/j.2042-7158.1996.tb05904.x